Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARG | Q86W56 | 5/20 | 0.37 |
| ▸ | SCN8A | Q9UQD0 | 4/20 | 0.37 |
| ▸ | SCN1A | P35498 | 3/20 | 0.35 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.32 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.32 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.32 |
| ▸ | TNNI3K | Q59H18 | 3/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31269244 | 0.91 | KMT2A (0.34) | PARGSCN8ASCN1APIK3CDKCNH2 | |
| SCHEMBL31268984 | 0.91 | PIK3CD (0.33) | PARGSCN8ASCN1APIK3CDKCNH2 | |
| SCHEMBL31269077 | 0.86 | HAVCR2 (0.33) | SCN8APIK3CDKCNH2SCN5ASCN9A | |
| SCHEMBL31269441 | 0.85 | KCNH2 (0.36) | PIK3CDKCNH2SCN5ASCN9ACNR1 | |
| SCHEMBL30983829 | 0.85 | KCNH2 (0.34) | PIK3CDKCNH2SCN5ASCN9ACNR1 | |
| SCHEMBL31269215 | 0.85 | KCNH2 (0.34) | PIK3CDKCNH2SCN5ASCN9ACNR1 | |
| SCHEMBL30983779 | 0.85 | KCNH2 (0.36) | PIK3CDKCNH2SCN5ASCN9ACNR1 | |
| SCHEMBL31269478 | 0.85 | SYK (0.36) | PIK3CDKCNH2SCN5ASCN9A | |
| SCHEMBL31268885 | 0.84 | PIK3CD (0.33) | PIK3CDKCNH2SCN5ASCN9A | |
| SCHEMBL31269475 | 0.83 | PIK3CD (0.37) | PIK3CDKCNH2SCN5ASCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4689155-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | Astrazeneca AB (SE) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024201368-A1 | USE OF INHIBITORS TO INCREASE EFFICIENCY OF CRISPR/CAS INSERTIONS | ASTRAZENECA AB (SE) | 2024-10-03 | — | — | WO | disclosed |